FILTER
FILTERED INTERVIEW RESULTS
David DeJean
SENIOR VICE PRESIDENT, SYSTECH INTERNATIONAL
Systech International is a technology leader in supply chain safety and brand protection.
Krishna Kanumuri
CEO, SAI LIFE SCIENCES
Sai Life Sciences delivers advanced discovery, contract development and manufacturing solutions through a broad suite of capabilities across the molecular lifecycle.
Pelin İșçener
MARKETING AND SALES DIRECTOR, ECZACIBAȘI MONROL NÜKLEER ÜRÜNLER
Eczacıbaşı Monrol specializes in producing agents for PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) scans, which are critical for detecting cancer, cardiological diseases and brain disorders, among other serious diseases.
Cem Erdem
CO-FOUNDER AND CEO, FLORABIO TEKNOLOJI
Florabio is a life science company with proprietary technology, know-how and experience in research and development of therapeutic proteins.
Muzaffer Bal
GENERAL MANAGER, ALI RAIF
Ali Raif is one of the oldest Turkish Pharmaceutical companies, and has developed from manufacturing and marketing under license to producing generics and other drugs.
Robert Foster
CEO, HEPION PHARMACEUTICALS
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease.
Daniel J O’Connor
PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using its plasmid DNA delivery platform.
Manni Kantipudi
CEO, GVK BIO
GVK BIO is a global Contract Research & Development Organization providing drug discovery and development services to the biopharma industry and experiencing rapid growth.
Girish Chovatia
CHAIRMAN AND MANAGING DIRECTOR, AMI LIFE SCIENCES
Ami Life Sciences is research driven generic API manufacturer as well as working on custom synthesis of New Chemical Entities.
Rahul Maheshwari
MANAGING DIRECTOR, DEFI HEALTHCARE
DEFI Healthcare is an Ahmedabad-based pharmaceutical company involved in the manufacturing and supply of a wide range of avant-garde pharmaceuticals to semi-regulated and non-regulated markets across the globe.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
